COMPLETED

High Confusion: Cannabis & Driving

Talk to us

Conditions

Impairment, CognitiveImpairment of AttentionImpairment, Psychomotorcannabisimpairmenttetrahydrocannabinol

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to assess the feasibility of administrating Δ9-THC and Δ8-THC isolates and simultaneously adopting several data harmonization measures to generate uniquely translatable data. This project aims to (1) evaluate the feasibility and acceptability of administering ∆9-THC and Δ8-THC isolates using standardized cannabis dosing units to quantify ∆9-THC and Δ8-THC pharmacokinetics; and (2) evaluate the feasibility and acceptability of adopting standardized impairment detection methods and driving performance definitions and measures on quantifying ∆9-THC and Δ8-THC driving impairment compared to a placebo.

Official Title

High Confusion: Evaluating Effects of Popular Cannabis Isolates on Driving Performance

Quick Facts

Study Start:2025-01-25
Study Completion:2025-09-16
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06236815

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 49 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * At least 18 years of age, no older than 49 years of age
  2. * Recent cannabis use (within past two years)
  3. * Good mental health as determined by self-reported responses to the Psychopathology Screener
  4. * Absence of any major medical, cardiovascular, endocrine, and neurological condition as determined by self-reported responses to the Medical History Screener
  5. * In possession of a valid drivers' license with at least two years of driving experience
  6. * English-speaking (able to provide consent and complete questionnaires)
  7. * Written Informed Consent
  1. * Any serious prior adverse response to cannabis
  2. * History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener
  3. * Pregnancy or lactation (pregnancy test, if needed)
  4. * Use of medications that may impact driving ability (e.g., mood stabilizers, sedatives)

Contacts and Locations

Principal Investigator

Heather Barkholtz, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

University of Wisconsin
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Heather Barkholtz, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-25
Study Completion Date2025-09-16

Study Record Updates

Study Start Date2025-01-25
Study Completion Date2025-09-16

Terms related to this study

Keywords Provided by Researchers

  • cannabis
  • impairment
  • tetrahydrocannabinol

Additional Relevant MeSH Terms

  • Impairment, Cognitive
  • Impairment of Attention
  • Impairment, Psychomotor